Page 1

EGETIS THERAPEUTICS Half - Year report January - June 2021 Emcitate development program progressing according to plan Financial overview April - June • Quarterly net revenues MSEK 25.0 ( 21.7 ) Quarterly loss MSEK -34.3 ( -36.2 ) • • • Cash and cash equivalents MSEK 207.4 ( 184.5 ) Cash flow for the period MSEK - 41.8 ( -33.8 ) Loss per share before / after dilution SEK -0.2 ( -0.7 ) Significant events during the period April - June • Kristina Sjöblom Nygren , MD , joined Egetis Therapeutics as Chief Medical Officer ( CMO ) and Yilmaz Mahshid , PhD , joined Egetis Therapeutics as Chief Financial Officer ( CFO ) . • Dr Thomas Lönngren ( Chairman ) and Mats Blom were elected as new Directors of the Board at the Annual General Meeting on the 29th of April . Emcitate • • Patient recruitment in the pivotal Phase IIb / III early intervention study with the drug candidate Emcitate progresses according to plan . Patient recruitment is expected to be completed in Q4 2021 . Continued interest in the opportunity to treat MCT8 deficiency with Emcitate from physicians across the globe . Emcitate is supplied on a named patient basis in several countries , following special approval from the national regulatory authority with more than 120 patients in total already getting access to Emcitate treatment . Financial overview January - June Net revenues for the period MSEK 28.8 ( 33.2 ) Loss for the period MSEK -53.6 ( -79.0 ) Cash and cash equivalents MSEK 207.4 ( 184.5 ) Cash flow for the period MSEK -80.1 ( -71.1 ) Loss per share before / after dilution SEK -0.3 ( -1.5 ) Aladote Aladote was presented at the scientific meeting of the American College of Medical Toxicology ( ACMT ) on April 14 , under the heading Antidote Updates . Preparation for the pivotal Phase IIb / III study for Aladote continues targeting study start at the end of 2021 , pending the COVID - 19 pandemic situation . PledOx® The company has parked further PledOx development following the POLAR results . Our partner Solasia Pharma KK will continue the pre- clinical program in taxane induced peripheral neuropathy . Significant events after the reporting period The results of the prematurely discontinued POLAR program with PledOx were presented at the ESMO World Congress on Gastrointestinal Cancer on July 2 . Financial overview 2021 2020 Apr - Jun Apr - Jun 2021 Jan - Jun Net revenues , KSEK 25,034 21,697 28,822 2020 Jan - Jun 33,201 2020 Jan - Dec Result after tax , KSEK -34,326 -36,164 -53,641 -78,983 40,662 -179,120 Cash flow , KSEK -41,768 -33,802 -80,129 -71,063 34,223 Cash , KSEK 207,411 184,470 207,411 184,470 287,850 Equity ratio % 69 % 86 % 69 % 86 % 70 % Earnings per share , SEK -0.2 -0.7 -0.3 -1.5 -2.7 Earnings per share after dilution , SEK -0.2 -0.7 -0.3 -1.5 -2.7 Average number of employees 10 9 10 9 9 Egetis Therapeutics Half - Year report January - June 2021 1